Please assess the completion status of the following clinical trial:

Trial Title: FIasp® vs. Novolog® in Type 1 Diabetics Using 670G Medtronic Pump

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial~2. Male or female, age ≥18 years at the time of signing informed consent~3. Documented diagnoses of T1DM ≥1 year prior to the day of screening~4. Using the Medtronic pump Minimed 670G for CSII in a basal-bolus regimen with a rapid acting insulin analogue for at least 30 days prior to screening and willing to continue using their personal Medtronic Minimed 670G and CSII for insulin treatment throughout the trial.~5. Ability and willingness to use the same insulin infusion sets throughout the trial~6. Using the same insulin for at least 30 days prior to screening~7. HbA1c \< 8.5% as assessed by local laboratory at screening~8. BMI ≤ 35.0 kg/m2 at screening~9. Ability and willingness to adhere to the protocol including performing SMPG profiles, attending visits, utilizing the auto mode feature of the pump for at least 80 % of the time during the study, and completing meal tests~Exclusion Criteria:~1. Known or suspected hypersensitivity to trial products or related products~2. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive methods (adequate contraceptive measures as required by local regulation or practice)~3. Participation in another clinical trial within 28 days before the screening visit. Note: clinical trials do not include non-interventional studies~4. Anticipated significant change in lifestyle (e.g. eating, exercise or sleeping pattern) throughout the trial~5. Any of the following: myocardial infarction, stroke, hospitalization for unstable angina or transient ischemic attack within the past 180 days prior to the day of screening~6. Subjects classified as being in New York Heart Association (NYHA) Class IV at screening~7. Planned coronary, carotid or peripheral artery revascularization known on the day of screening.~8. Inadequately treated blood pressure defined as Grade 3 hypertension or higher (Systolic~   ≥180 mmHg or diastolic ≥110 mmHg) at screening~9. Impaired liver function, defined as ALT ≥ 2.5 times upper normal limit at screening~10. Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) value of \< 45 ml/min/1.73 m2~11. Anticipated initiation or change in concomitant medications (for more than 14 consecutive days) known to affect weight or glucose metabolism in the opinion of the Investigator~12. Proliferative retinopathy or maculopathy requiring acute treatment at the time of screening~13. History of hospitalization for ketoacidosis ≤180 days prior to the day of screening~14. Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 30 days before screening~15. Presence of malignant neoplasms at the time of screening. Basal and squamous cell skin cancer and any carcinoma in-situ is allowed.~16. Reoccurring Severe hypoglycemia while on the Medtronic Minimed 670G in the investigators opinion~17. Any condition which, in the opinion of the Investigator, might jeopardize Subject's safety or compliance with the protocol~    -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fiasp/Novolog (Type: EXPERIMENTAL): 7 weeks on Fiasp® then crossover to 7 weeks on Novolog® in subjects on the 670g Hybrid Closed Loop Continuous Subcutaneous Insulin Infusion
- Novolog/Fiasp (Type: EXPERIMENTAL): 7 weeks on Novolog® then crossover to 7 weeks on Fiasp® in subjects on the 670g Hybrid Closed Loop Continuous Subcutaneous Insulin Infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).